HPS Group is a solution-oriented health policy and public affairs company.
Its specialty is strategic counsel that integrates the perspectives of Congress, the Executive Branch, third parties, and the media. The company philosophy is “Think. Plan. Act.”
Because of Mr. Grossman’s expertise and experience, HPS Group is often asked to partner with larger firms in assisting clients with complex, multi-faceted projects.In addition to being an analyst, counselor and communicator, Mr. Grossman is a facilitator for strategic planning and program development meetings. He speaks and writes on a wide range of policy topics and has his own blog, FDA Matters, at www.fdamatters.com.
From 1989 to 2000, Mr. Grossman was senior managing director and director of health policy in Hill and Knowlton’s
In 1985, Mr. Grossman was appointed to serve as a Deputy Assistant Secretary for Health in the U.S. Department of Health and Human Services. During his four-year tenure, he was responsible for the development of health policy, planning, and evaluation for the U.S. Public Health Service. Among his accomplishments, he chaired the “long-term care” component of the Secretary’s initiative on catastrophic health care costs, coordinated the President’s response to his Commission on HIV Infection and AIDS, and served as Acting Chair of the Orphan Product Board.
Previously, Mr. Grossman was Health Staff Director and Majority Counsel to the Senate Committee on Labor and Human Resources (now Senate HELP Committee). He was one of the chief Senate negotiators on the Orphan Drug Act of 1983 and on the Drug Price Competition and Patent Term Restoration Act of 1984 (Hatch-Waxman). These laws have had significant and lasting impact on the development of new pharmaceutical products. Earlier in his career, while at the Association of American Medical Colleges, he was an analyst and advocate for the nation’s medical schools.
Mr. Grossman received a J.D. from